|Dr. Michael D. Clayman||Co-Founder, Pres, CEO & Director||883.23k||N/A||1952|
|Dr. Neil Bodick||Co-Founder & Chief Scientific Officer||602.06k||971.96k||1947|
|Mr. David A. Arkowitz||Chief Financial Officer||414.99k||N/A||1961|
|Mr. Mark S. Levine||Gen. Counsel & Sec.||544.39k||N/A||1973|
|Dr. Scott D. Kelley||Chief Medical Officer||540.56k||N/A||1959|
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee in the United States. The company also develops FX201 a gene therapy product candidate designed to stimulate the production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.
Flexion Therapeutics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 8. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 9.